New hope adding inhaled interferon to the arsenal
The trial examined 101 patients hospitalized with COVID-19. Those who inhaled an experimental type one interferon made by Synairgen were 79% less likely to develop severe disease and more than twice as likely to reach full recovery after 28 days than the placebo patients. Both findings reached statistical significance. The company’sstock soared more than 500% on the news.
The trial examined 101 patients hospitalized with COVID-19. Those who inhaled an experimental type one interferon made by Synairgen were 79% less likely to develop severe disease and more than twice as likely to reach full recovery after 28 days than the placebo patients. Both findings reached statistical significance. The company’sstock soared more than 500% on the news.
CTG Labs - NCBI
clinicaltrials.gov